Trevicta 175 mg, 263 mg, 350 mg, 525 mg Prolonged release suspension for injection.
PDF Leaflet Revision Date: 16 January 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Maintenance treatment of schizophrenia in stable adult patients.
Dosage (summary)
Administer 175-525 mg IM every 3 months after stabilization on 1-monthly paliperidone.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding due to potential risks to the newborn.
Key Drug Interactions
- QT prolonging agents
- Centrally acting medicines
- Dopamine agonists
Contraindications
- Hypersensitivity
- Moderate to severe renal impairment
- Parkinson's disease
- Dementia with Lewy Bodies
Common side effects
- Weight gain
- Upper respiratory tract infection
- Anxiety
- Headache
- Insomnia
Counselling Points
- Monitor for weight gain
- Avoid driving until effects are known
- Report signs of infection or hypersensitivity
Serious warnings
- Neuroleptic Malignant Syndrome
- Tardive dyskinesia
- Hyperglycaemia
- Orthostatic hypotension
Important Disclaimer
The Trevicta 175 mg, 263 mg, 350 mg, 525 mg Prolonged release suspension for injection. professional information leaflet below is the property of Janssen Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
